

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



天津發展控股有限公司  
TIANJIN DEVELOPMENT HOLDINGS LIMITED

*(Incorporated in Hong Kong with limited liability)*

**(Stock Code: 882)**

## **COMPLETION OF SHARE REPURCHASES AND ADOPTION OF SHARE AWARD SCHEME BY A LISTED SUBSIDIARY**

Reference is made to the announcement of Tianjin Development Holdings Limited (the “**Company**”) dated 20 December 2024 (the “**Announcement**”) in relation to the adoption of a share repurchase program and a share award scheme by its indirect non-wholly owned subsidiary, Tianjin Lisheng Pharmaceutical Co., Ltd. (天津力生製藥股份有限公司) (“**Lisheng Pharmaceutical**”). Unless otherwise specified, capitalised terms used herein shall have the meanings given to them in the Announcement.

### **SHARE REPURCHASES BY LISHENG PHARMACEUTICAL**

After the adoption of the Share Repurchase Program, from 25 December 2024 to 9 January 2025, Lisheng Pharmaceutical repurchased a total of 7,209,980 of its ordinary shares (“**Repurchased Shares**”), representing approximately 2.80% of its issued share capital, by way of centralised auction trading on the Shenzhen Stock Exchange for an aggregate amount of RMB129,410,070.56 (equivalent to approximately HK\$139,150,614) at the then prevailing market price, the highest and lowest repurchase prices of which were RMB18.50 and RMB17.28 per share of Lisheng Pharmaceutical respectively, and the repurchase price does not exceed the Maximum Price of RMB21.22 per share of Lisheng Pharmaceutical. Accordingly, the Share Repurchase Program has been fully implemented.

All those 7,209,980 Repurchased Shares will be used as the Restricted Shares to be granted to the Participants of the Share Award Scheme, and there will be no new share of Lisheng Pharmaceutical to be issued for the purpose of the Share Award Scheme.

### **ADOPTION OF SHARE AWARD SCHEME BY LISHENG PHARMACEUTICAL**

The resolutions in relation to the approval of the Share Award Scheme were duly passed by the shareholders of Lisheng Pharmaceutical at its general meeting held on 5 February 2025. Accordingly, the Share Award Scheme has been duly adopted and will be implemented by Lisheng Pharmaceutical according to the principal terms as previously stated in the Announcement.

As at the date of this announcement, the Company has an effective interest of approximately 34.08% in the issued share capital of Lisheng Pharmaceutical.

*In this announcement, RMB has been converted to HK\$ at the rate of RMB0.93 = HK\$1.00 for illustration purpose only. No representation is made that any amounts in RMB or HK\$ have been, could have been or could be converted at the above rate or at any other rates or at all.*

By Order of the Board  
**Tianjin Development Holdings Limited**  
**Teng Fei**  
*Chairman and Executive Director*

Hong Kong, 6 February 2025

*As at the date of this announcement, the Board of the Company consists of Mr. Teng Fei, Dr. Zhai Xinxiang, Mr. Xia Binhui, Mr. Sun Lijun\*, Ms. Ng Yi Kum, Estella\*\*, Mr. Wong Shiu Hoi, Peter\*\*, Mr. Lau Ka Keung\*\* and Mr. Sin Hendrick\*\*.*

\* *non-executive director*

\*\* *independent non-executive director*